U.S. Markets close in 2 hrs 35 mins

Proteostatis stock plunges on cystic fibrosis triple combo data

Allison DeAngelis
Proteostatis stock plunges on cystic fibrosis triple combo data

What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.